서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 181 to 197 of 197

Issue DateTitle / Author(s) / CitationFileAltmetrics
2019-09
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-11
Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
view fileDOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2019-11
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
view filelink
2020
Treatment Strategy for Papillary Renal Cell Carcinoma Type II base on Genetic Analysis
view filelink
2020
The Comprehensive Analysis of Genomic, Transcriptomic, and Pathologic Changes after Acquisition of Resistance to Immune Checkpoint Inhibitors
view filelink
2020
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
view fileDOI
2020
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
DOI
2020-01
Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial
DOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2020-12
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2021-11
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC
DOI
1 2 3 4